Apellis Pharmaceuticals withdraws $86 mln IPO

Apellis Pharmaceuticals Inc withdrew its plans for an initial public offering, according to an SEC filing. Apellis, which is developing a protein inhibitor for autoimmune and inflammatory diseases, originally applied to list on the NASDAQ in October 2015 with a proposed deal size of $86 million.